Teresa Reguly

Registered Patent Agent, (highest overall exam mark in Canada), 2008, Canadian Patent Office
JD, 2006, University of Toronto
PhD (Molecular and Medical Genetics), 2003, University of Toronto
BSc (Molecular and Medical Genetics, With High Distinction), 1998, University of Toronto


Teresa’s practice focuses on advising clients that sell regulated products in the food, pharmaceutical, biotechnology and medical device industries. Teresa advises on intellectual property and regulatory issues, in particular, patent and regulatory matters in the chemical, biochemical and pharmaceutical fields, and has experience with drafting, filing and prosecuting patent applications, and advising on validity, patentability and infringement of intellectual property rights.

Teresa has been involved in drafting and negotiating IP licensing, research and development, co-promotion, marketing and confidentiality agreements for her clients, and provides guidance in Food and Drugs Act compliance, establishment licensing, product licensing, packaging and labeling, drug pricing and formulary listings.

She also has expertise in advertising and promotion of consumer products, food and health products, as well as mandatory reporting and corrective actions. She also advises clients in a range of industries on privacy issues, cross-border transfer of personal information, and compliance with privacy law obligations.

Teresa is a registered patent agent in Canada. In September 2009, she was awarded for having achieved the highest overall mark in Canada on the 2008 patent agent exams.


Chambers & Partners’ Chambers Canada—Leading lawyer in life sciences (2019)

Lexpert/Thomson Reuter’s Canadian Legal Lexpert Directory—Repeatedly recommended in biotechnology (2018-2019)

Chambers & Partners’ Chambers Global: The World’s Leading Lawyers for Business, the Client’s Guide 2011 and 2012—Associate to watch in intellectual property

Teresa was named as a leading lawyer to watch intellectual property by Lexpert in 2017.

Representative Work

  • Amgen in its successful Stage 3 appeal before the Pharmaceutical Advertising Advisory Board (PAAB) concerning the issue of whether a journal interview is “paid advertising” under the PAAB Code, the first Stage 3 hearing heard by the PAAB in over a decade
  • Merus Labs in its C$342 million sale to Norgine B.V.
  • OvaScience in its offering of the AUGMENT fertility treatment in select in vitro fertilization (IVF) clinics in Canada
  • Imperial Capital Group and OPTrust Private Markets Group in their C$121 million investment in Dental Corporation of Canada Holdings Inc.
  • Loblaw in its C$12.4 billion acquisition of Shoppers Drug Mart Corporation, one of Canada’s most recognized retail brands
  • a global biopharmaceutical company in defence of a marketing complaint brought by a competitor before the Industry Practices Review Committee (IPRC) of Rx&D
  • Nordion in the US$200 million sale of TheraSphere®, its targeted therapies division, to BTG plc
  • Pfizer Canada, as Canadian counsel, in the spinoff and cross-border reorganization of its Canadian animal health-care business into the new U.S.-based, public entity, Zoetis Inc.

Professional Involvement

Teresa worked with the LSUC on an e-Course titled “Privacy Law Basic for Business Lawyers”. The e-Course explains the privacy law obligations of a corporation in three situations: on an ongoing basis, in the course of a transaction, and upon a privacy breach. It provides a foundation in privacy law for business lawyers of all experience levels.

Before joining Torys, Teresa was a research associate at the Samuel Lunenfeld Research Institute in Toronto.

Memberships and Affiliations

Teresa is a member of the Toronto Intellectual Property Group, the Intellectual Property Institute of Canada and the American Intellectual Property Law Association. She is also on the Global Committee for the Food and Drug Law Institute.


The challenge of consumer disclosure
September 19, 2019

Québec court strikes down prohibition on growing cannabis at home
September 10, 2019

Drug price cooling in Canada’s election year: Release of final PMPRB regulations
August 14, 2019

FCA sends Differin pricing matter back to PMPRB
August 13, 2019

Health Canada updates its guidance on promotion of health products
July 31, 2019

Federal Court of Appeal’s ruling on the judicial review of PMPRB decision on Differin
July 12, 2019

Let them eat cannabis! An update on Canada’s final regulations
July 09, 2019

Is national pharmacare coming to Canada?
July 08, 2019

PMPRB decision stands: Soliris priced excessively
June 25, 2019

Simplifying access to unauthorized drugs in Canada
June 13, 2019

No site, no review: Health Canada announces new cannabis license application requirements
May 15, 2019

Plain and standardized: A new look for tobacco
May 13, 2019

Updates in International Food Regulation and Trade: Foreign Supplier Verification Program, Efforts in Harmonization, and the United States-Mexico-Canada Agreement
May 03, 2019

Proposed changes to Canadian regulation affecting generic drug submissions and data protection
April 10, 2019

Canada: Another step towards national pharmacare
April 03, 2019

Public access to clinical information on drugs and medical devices granted
April 01, 2019

Prosecution history estoppel comes to Canada
February 20, 2019

Consultation now open on draft guidance on Software as Medical Device regulation
February 07, 2019

Let them eat cannabis – with restrictions!
January 02, 2019

Further Details of Ontario’s Private Retail Market for Cannabis Unveiled
November 22, 2018

The USMCA: Good News for Intellectual Property Rights Holders
October 16, 2018

Ontario Opens up the Cannabis Retail Market
October 11, 2018

Ottawa CARE Regional Congress
September 14, 2018

Federal Court Addresses the Intention and Application of Vanessa’s Law
July 24, 2018

Surviving and Thriving in the Post-Legalization Cannabis Industry
July 19, 2018

Chambers Global Practice Guides: Life Sciences
Author, Canada Law and Practice Chapter

July 2018

Le gouvernement du Québec limitel’utilisation des programmes de fidélisation et de soutien aux patients dans un nouveau projet de règlement
July 17, 2018

Québec Government Limits use of Loyalty Cards and Patient Support in Draft Regulation
July 17, 2018

Cannabis Legalization One Step Closer With Regulations Finalized
July 05, 2018

A New Leaf for Canada: Senate Passes Draft Cannabis Act
June 21, 2018

PharmaFocus 2022 Industry Briefing
April 25, 2018

The Regulatory Haze Around Cannabis Lingers On… But Greater Visibility for Packaging and Labelling Emerges
March 21, 2018

Free Trade Deal Reached After 11 Countries Sign CPTPP
March 13, 2018

Phased Approach Announced for Proposed Changes to Self-Care Product Regulation
March 08, 2018

Ontario: First Province to Introduce Regulatory Proposals on Cannabis
February 20, 2018

Further Price Reductions for High-Use Generic Drugs
February 12, 2018

Reduced Physical Security Requirements for Cannabis Producers
February 01, 2018

Alexion Pharmaceuticals v Canada FCA Dismisses Appeal Aimed at Constitutionality of PMPRB Provisions
December 21, 2017

First Out of The Gate Again: Ontario’s Cannabis Legislation Becomes Law
December 20, 2017

Potential Change in Store for Regulating Disclosure of Clinical Information
December 19, 2017

Proposed PMPRB Regulations Published for Comment
December 05, 2017

Government of Canada Releases Proposed Cannabis Regulatory Framework
November 28, 2017

Galderma Successful in Judicial Review of PMPRB Decision on Differin
November 15, 2017

What you need to know – Marketing Drugs in the U.S.
November 08, 2017

Regulations on Drug Manufacturers and Pharmacists Proposed for Québec
October 16, 2017

Alberta’s Proposed Cannabis Framework
October 12, 2017

Proposed Amendments to Canada’s Cannabis Act
October 11, 2017

More Transparency in Health Care: Ontario’s Proposed “Sunshine” Legislation
October 05, 2017

Alexion Ordered to Significantly Reduce Cost of Soliris
October 04, 2017

Finalizing Patent Term Extension in Canada
September 14, 2017

Monopoly on Cannabis: Ontario’s Plan for Retail Sales
September 11, 2017

Ontario Consultations on Disclosure of Payments in the Health Care Sector
August 09, 2017

The Cap Is Back: Québec to Reinstate Professional Allowances Cap
August 01, 2017

Canada Edges Toward Patent Term Extension
July 24, 2017

New Rule Clarifies Circumstances Requiring Breach Reporting Under Ontario PHIPA
July 18, 2017

Access to Information Reforms Expand Powers of Information Commissioner
July 11, 2017

Governments Turn to Public to Develop Cannabis Laws
June 21, 2017

Overhaul to Drug Pricing Regime Proposed in Canada
June 01, 2017

Canada 101 Biopharmaceutical Opportunities
May 24, 2017

Breaking Ground: Canada’s Cannabis Framework
April 19, 2017

Keyword Advertising May Be Confusing After All
April 11, 2017

Regulatory Roles and Issues in Corporate Transactions
April 04, 2017

Health Canada Proposal to Release Clinical Information in Drug Submissions and Medical Device Applications
March 31, 2017

Intellectual Property Owners Association (IPO) Canadian Practice
Speaker, “PMPRB Jurisdiction and Recent Developments”
March 28, 2017

2016 in Review: Canada Implements New Changes to Promote Healthier Living
March 10, 2017

Keyword Advertising May Be Confusing After All
February 13, 2017

Trump Executive Order Minimizes U.S. Privacy Act Protections for Non-U.S. Citizens
February 06, 2017

New Report on Novel Foods from Genetically Modified Animals and Labelling of GMOs
February 02, 2017

Les effets du Projet de loi 92 sur les ententes entre les fabricants et les pharmacies et sur le soutien aux patients
January 24, 2017

The Impact of Québec’s Bill 92 on Arrangements between Manufacturers and Pharmacies, and Patient Support
January 24, 2017

Ontario Expands Pharmacists’ Vaccine Access and Administration
January 04, 2017

Task Force Recommendations Pave the Way to Cannabis Legalization
December 20, 2016

Consultations Open as Health Canada Continues Roll-Out of Healthy Eating Initiatives
November 23, 2016

Eat Your Greens! Health Canada Announces New Healthy Eating Strategy
November 10, 2016

Changes Ahead for Natural Health Products, Non-Prescription Drugs and Cosmetics Regulation in Canada
September 21, 2016

Québec Publishes Draft Regulation on Calls for Tenders for Provision or Supply of Medications
September 06, 2016

New Rules on Access to Cannabis for Medical Purposes
August 24, 2016

PMPRB to Reform its Guidelines
July 07, 2016

Canada’s Privacy Commissioner Enters the CASL Enforcement Ring
May 31, 2016

Health Canada Ordered to Grant Licence for Resolve
May 16, 2016

Privacy Obligations for Organizations and Employee Snooping
April 25, 2016

Expanding Your Marketplace: Guidance for US Businesses Working Globally
March 15-17, 2016

2015 Year in Review—Top 10 Food Regulatory Issues in Canada
February 17, 2016

Post-Filing Amendments to Drug Submissions Can Trigger Data Protection
November 27, 2015

Generic Drug Manufacturers Not Off the Hook: Federal Court of Appeal
November 18, 2015

Year in Review—Top 10 Issues for Drugs and Devices in Canada in 2015
November 10, 2015

Health Canada Interim Policy Clarifies Interpretation of “Medicinal Ingredient,” Product Labelling, and Pharmaceutical Equivalence
July 03, 2015

Narrow Window to Resubmit Patent Lists: Changes to “Canada’s Orange Book” Regulations Now in Force
June 26, 2015

Long-Awaited PIPEDA Amendments Become Law
June 23, 2015

Ontario to strengthen health privacy laws
June 22, 2015

Nutrition Label Changes Proposed by Health Canada
June 17, 2015

Ontario Legislates Posting Calories on Menus
June 03, 2015

Product Listing Agreements Come to Québec
May 12, 2015

New Searchable Database: Drug and Health Product Inspection
April 27, 2015

Implementing Vanessa’s Law: Draft Guidance from Health Canada
April 16, 2015

New Draft Guide: Labelling and Packaging Medication in Canada
April 10, 2015

New Pilot Program to Streamline Cosmetic and Drug Imports
March 23, 2015

Court of Appeal affirms: privacy tort applies to breach of private health information
February 23, 2015

Health Canada Announces New Measures to Monitor Prescription Drug Shortages
February 17, 2015

Ontario Proposes Changes to Generic Drug Benefit Pricing
November 12, 2014

Proposed Changes to the Medical Devices Regulations
October 30, 2014

Privacy tort applies to breach of private health information
October 02, 2014

Canada Introduces Changes to the Requirements for Labelling, Packaging and Brand Names of Drugs
August 19, 2014

Federal Court Considers PMPRB Jurisdiction Over Generic Manufacturers
July 07, 2014

Proposed Treatment of Confidential Business Information Under Vanessa’s Law (Bill C-17)
July 02, 2014

Federal Court Limits Third-party Information Exemptions in Access-to-information Requests to Regulators
May 28, 2014

Drugs and Devices: U.S./Canadian Patent Infringement Laws and Health Canada’s LASA Guidance
Speaker, FDLI’s Canadian and U.S. Food, Drug, Cosmetics & Device Regulation: Key Developments and Comparisons
May 15, 2014

Look Before You Leap: Pre-Canadian Launch Regulatory Considerations for U.S. Companies
May/June 2014 Edition

Ontario Government Urged to Reconsider Rules for Value Adds in RFPs for Drug Products
April 17, 2014

Proposed Privacy Reforms Made Public
April 11, 2014

The CADTH Releases Submission Guidelines for Biosimilars
March 28, 2014

Proposed Post-market Safety Amendments to Food and Drugs Act
December 13, 2013

Data Protection in Canada: Court of Appeal Confirms Narrow Approach
January 30, 2013

Sale of Unlicensed Natural Health Products in Canada to End
January 28, 2013

Canada’s PAAB Releases Updated Code of Advertising Acceptance
December 07, 2012

Health Canada Announces Intent to Develop a Framework for Orphan Drug Approval
October 05, 2012

Drafting Rights, Obligations, Exclusion and Limitation Clauses
Speaker, Federated Press’s 5th Essentials of Commercial Contracts Course, Toronto
June 05, 2012

Canada to Change the Regulation of “Food-Like” Natural Health Products
April 24, 2012

Health Canada’s Guidance Document on PM(NOC) Regulations Now Finalized
April 04, 2012

Ontario Companies Doing Business with Hospitals May Become Subject to Access-to-Information Requests
Westlaw Journal: Medical Devices, vol. 18, issue 8
June 2011

Ontario Government Seeks Appeal of Pharmacies’ Successful Challenge on Private Label Restrictions
Food and Drug Regulatory Bulletin
February 24, 2011

Patents and Patent Litigation
Lecturer, University of Waterloo, School of Pharmacy
June 14, 2010

Drafting Rights, Obligations, Exclusion and Limitation Clauses Workshop
Co-leader, Federated Press’s Essentials of Commercial Contracts Course
May 27, 2010

Canada’s Approach to Functional Foods
Update magazine, Issue 2
March/April 2010

Introduction to Patents
Lecturer, York University, Schulich School of Business
March 23, 2010

Introduction to Intellectual Property and Regulatory Issues for Drug Products in Canada
Lecturer, University of Waterloo, School of Pharmacy (Health Sciences)
March 22, 2010 and March 28, 2011

CIPO’s New Draft Guidelines Could Result in Higher Disclosure Standards for Canadian Patents
November 25, 2009

Canada Proposes Amendments to Adverse Drug Reaction Reporting
Reproduced with permission of the publisher from Health Law in Canada, vol. 30, no. 1
October 2009

Biosimilars in Canada: New Draft Guidelines from Health Canada
Update magazine, Issue 4
July/August 2009

8th Edition Drug Patent and Legal Forum
Speaker, St. Andrews Club & Conference Centre, Toronto
May 28 – 29 2009

Data Protection for “Innovative Drugs” – Guidance Now Final
April 02, 2009


June 03, 2015: Torys’ IP Lawyers Comment on the Canadian Patent System in Lexpert

May 07, 2012: Canadian government plan to eliminate Schedule F an opportunity for US companies that are looking to get their products more easily to consumers in Canada, says Teresa Reguly in The Tan Sheet

July 24, 2009: Teresa Reguly to receive award for achieving the highest overall mark in Canada on the 2008 Patent Agent Examinations